Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hepatitis A vaccine.

Beth P Bell1

  • 1Epidemiology Branch, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA.

Seminars in Pediatric Infectious Diseases
|August 30, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Surveillance for adverse events following use of live attenuated chikungunya vaccine, United States, 2024, and the associated public health response in 2024 and 2025.

Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin·2025
Same author

Use of JYNNEOS (Smallpox and Mpox Vaccine, Live, Nonreplicating) for Persons Aged ≥18 Years at Risk for Mpox During an Mpox Outbreak: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023.

MMWR. Morbidity and mortality weekly report·2025
Same author

Development of COVID-19 vaccine policy - United States, 2020-2023.

Vaccine·2023
Same author

Use of Updated COVID-19 Vaccines 2023-2024 Formula for Persons Aged ≥6 Months: Recommendations of the Advisory Committee on Immunization Practices - United States, September 2023.

MMWR. Morbidity and mortality weekly report·2023
Same author

Interim Recommendations from the Advisory Committee on Immunization Practices for the Use of Bivalent Booster Doses of COVID-19 Vaccines - United States, October 2022.

MMWR. Morbidity and mortality weekly report·2022
Same author

Interim Recommendation of the Advisory Committee on Immunization Practices for Use of the Novavax COVID-19 Vaccine in Persons Aged ≥18 years - United States, July 2022.

MMWR. Morbidity and mortality weekly report·2022
Same journal

Editorial.

Seminars in pediatric infectious diseases·2020
Same journal

Viral pharyngitis.

Seminars in pediatric infectious diseases·2020
Same journal

The epidemiology of respiratory infections in children.

Seminars in pediatric infectious diseases·2020
Same journal

Antiviral agents in the critically ill child.

Seminars in pediatric infectious diseases·2020
Same journal

Serious and lethal respiratory tract infections of viral etiology in children.

Seminars in pediatric infectious diseases·2020
Same journal

Subject index.

Seminars in pediatric infectious diseases·2020
See all related articles

Hepatitis A vaccination is a powerful tool against this infectious disease. Routine childhood vaccination in high-incidence areas significantly reduces Hepatitis A rates, highlighting the importance of ongoing vaccination efforts.

Area of Science:

  • Epidemiology
  • Vaccinology
  • Public Health

Background:

  • Hepatitis A is a common infectious disease in the United States, with significant underreporting.
  • The fecal-oral route is the primary mode of Hepatitis A virus (HAV) transmission, often involving children.
  • Inactivated Hepatitis A vaccines offer a safe and effective prevention method.

Purpose of the Study:

  • To evaluate the impact of Hepatitis A vaccination on disease incidence.
  • To assess the role of childhood vaccination in controlling Hepatitis A outbreaks.
  • To underscore the importance of vaccination coverage and ongoing surveillance.

Main Methods:

  • Analysis of reported Hepatitis A cases and vaccination strategies.
  • Monitoring disease incidence in relation to vaccination program implementation.

Related Experiment Videos

  • Review of vaccine safety, immunogenicity, and efficacy data.

    • Main Results:

    • Hepatitis A vaccines are safe, immunogenic, and efficacious, providing short- and long-term protection.
    • Routine vaccination of children in high-incidence areas has led to substantial decreases in Hepatitis A rates.
    • Children play a key role in HAV transmission due to asymptomatic infections.

    Conclusions:

    • Hepatitis A vaccination is a highly effective public health intervention.
    • Targeted childhood vaccination programs can dramatically reduce disease incidence.
    • Continued monitoring and improved vaccination coverage are crucial for long-term control of Hepatitis A.